Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buparlisib + goserelin + tamoxifen
- Development stage
- Phase 1
- Lead developer
- Adlai Nortye
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
A combination therapy consisting of buparlisib (a pan-class I PI3K inhibitor), goserelin (a GnRH agonist), and tamoxifen (a selective estrogen receptor modulator). This regimen targets multiple pathways in hormone receptor-positive breast cancer: buparlisib inhibits the PI3K/AKT/mTOR pathway, tamoxifen blocks estrogen receptors, and goserelin suppresses ovarian function in premenopausal women.
- Other names
- buparlisib + tamoxifen + goserelin
02
Targets
ER (Estrogen receptor)GnRHR (Gonadotropin-releasing hormone receptor)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)
Beyond the preview
Go deeper on buparlisib + goserelin + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buparlisib + goserelin + tamoxifen.